{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T22:20:07Z","timestamp":1792794007254,"version":"4.5.0"},"reference-count":165,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,2,27]],"date-time":"2019-02-27T00:00:00Z","timestamp":1551225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008594","name":"European Hematology Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008594","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2019.00337","type":"journal-article","created":{"date-parts":[[2019,2,27]],"date-time":"2019-02-27T04:39:15Z","timestamp":1551242355000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":96,"title":["Complement in Thrombotic Microangiopathies: Unraveling Ariadne's Thread Into the Labyrinth of Complement Therapeutics"],"prefix":"10.3389","volume":"10","author":[{"given":"Eleni","family":"Gavriilaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Achilles","family":"Anagnostopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios C.","family":"Mastellos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2019,2,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1182\/asheducation-2012.1.617","article-title":"Atypical hemolytic uremic syndrome: what is it, how is it diagnosed, and how is it treated?","volume":"2012","author":"Nester","year":"2012","journal-title":"Hematology Am Soc Hematol Educ Prog."},{"key":"B2","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.blre.2017.02.003","article-title":"Complementopathies","volume":"31","author":"Baines","year":"2017","journal-title":"Blood Rev."},{"key":"B3","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.transci.2016.04.011","article-title":"Defining the genetics of thrombotic microangiopathies","volume":"54","author":"Vieira-Martins","year":"2016","journal-title":"Transfus Apher Sci."},{"key":"B4","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s00467-015-3076-8","article-title":"An international consensus approach to the management of atypical hemolytic uremic syndrome in children","volume":"31","author":"Loirat","year":"2016","journal-title":"Pediatr Nephrol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1111\/jth.13571","article-title":"Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies","volume":"15","author":"Scully","year":"2017","journal-title":"J Thromb Haemost."},{"key":"B6","doi-asserted-by":"publisher","first-page":"554","DOI":"10.2215\/CJN.04760512","article-title":"Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults","volume":"8","author":"Fremeaux-Bacchi","year":"2013","journal-title":"Clin J Am Soc Nephrol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1056\/NEJM197902153000717","article-title":"Decreased cold-insoluble globulin in congenital thrombocytopenia (Upshaw-Schulman syndrome)","volume":"300","author":"Rennard","year":"1979","journal-title":"N Engl J Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/BF02982558","article-title":"Upshaw-Schulman syndrome revisited: a concept of congenital thrombotic thrombocytopenic purpura","volume":"74","author":"Kinoshita","year":"2001","journal-title":"Int J Hematol."},{"key":"B9","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1182\/blood.V89.9.3097","article-title":"Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura","volume":"89","author":"Furlan","year":"1997","journal-title":"Blood"},{"key":"B10","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.1182\/blood.V91.8.2839.2839_2839_2846","article-title":"Acquired deficiency of von Willebrand factor-cleaving protease in a patient with thrombotic thrombocytopenic purpura","volume":"91","author":"Furlan","year":"1998","journal-title":"Blood"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1056\/NEJM199811263392203","article-title":"Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura","volume":"339","author":"Tsai","year":"1998","journal-title":"N Engl J Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1056\/NEJM199108083250604","article-title":"Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura","volume":"325","author":"Rock","year":"1991","journal-title":"Canadian Apheresis Study Group N Engl J Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.blre.2014.01.003","article-title":"Diagnosis and management of complement mediated thrombotic microangiopathies","volume":"28","author":"Cataland","year":"2014","journal-title":"Blood Rev."},{"key":"B14","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1056\/NEJMra1312353","article-title":"Syndromes of thrombotic microangiopathy","volume":"371","author":"George","year":"2014","journal-title":"N Engl J Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","article-title":"Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome","volume":"368","author":"Legendre","year":"2013","journal-title":"N Engl J Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"7195","DOI":"10.1074\/jbc.RA118.002639","article-title":"Brain microvascular endothelial cells exhibit lower activation of the alternative complement pathway than glomerular microvascular endothelial cells","volume":"293","author":"Sartain","year":"2018","journal-title":"J Biol Chem."},{"key":"B17","doi-asserted-by":"publisher","first-page":"2809","DOI":"10.1681\/ASN.2018070759","article-title":"Genetic analysis of 400 patients refines understanding and implicates a new gene in atypical hemolytic uremic syndrome","volume":"29","author":"Bu","year":"2018","journal-title":"J Am Soc Nephrol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/s41581-018-0098-z","article-title":"Endothelium structure and function in kidney health and disease Nat Rev Nephrol","volume":"15","author":"Jourde-Chiche","year":"2019"},{"key":"B19","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.molimm.2015.03.246","article-title":"Atypical aHUS: State of the art","volume":"67","author":"Nester","year":"2015","journal-title":"Mol Immunol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"3008","DOI":"10.3389\/fimmu.2018.03008","article-title":"Heme drives susceptibility of glomerular endothelium to complement overactivation due to inefficient upregulation of heme oxygenase-1","volume":"9","author":"May","year":"2018","journal-title":"Front Immunol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.kint.2016.03.023","article-title":"Von Willebrand factor regulates complement on endothelial cells","volume":"90","author":"Noone","year":"2016","journal-title":"Kidney Int."},{"key":"B22","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1093\/hmg\/ddi066","article-title":"Predisposition to atypical hemolytic uremic syndrome involves the concurrence of different susceptibility alleles in the regulators of complement activation gene cluster in 1q32","volume":"14","author":"Esparza-Gordillo","year":"2005","journal-title":"Hum Mol Genet."},{"key":"B23","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1136\/jmg.2005.030783","article-title":"The development of atypical haemolytic-uraemic syndrome is influenced by susceptibility factors in factor H and membrane cofactor protein: evidence from two independent cohorts","volume":"42","author":"Fremeaux-Bacchi","year":"2005","journal-title":"J Med Genet."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1084\/jem.20070301","article-title":"Spontaneous hemolytic uremic syndrome triggered by complement factor H lacking surface recognition domains","volume":"204","author":"Pickering","year":"2007","journal-title":"J Exp Med."},{"key":"B25","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1016\/j.molimm.2011.11.003","article-title":"Common genetic variants in complement genes other than CFH, CD46 and the CFHRs are not associated with aHUS","volume":"49","author":"Ermini","year":"2012","journal-title":"Mol Immunol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"4182","DOI":"10.1182\/blood-2011-10-383281","article-title":"A prevalent C3 mutation in aHUS patients causes a direct C3 convertase gain of function","volume":"119","author":"Roumenina","year":"2012","journal-title":"Blood"},{"key":"B27","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1681\/ASN.2012090884","article-title":"Combined complement gene mutations in atypical hemolytic uremic syndrome influence clinical phenotype","volume":"24","author":"Bresin","year":"2013","journal-title":"J Am Soc Nephrol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1182\/blood-2014-10-609073","article-title":"Mapping interactions between complement C3 and regulators using mutations in atypical hemolytic uremic syndrome","volume":"125","author":"Schramm","year":"2015","journal-title":"Blood"},{"key":"B29","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1182\/blood-2013-03-489245","article-title":"Complement activation by heme as a secondary hit for atypical hemolytic uremic syndrome","volume":"122","author":"Frimat","year":"2013","journal-title":"Blood"},{"key":"B30","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1681\/ASN.2013070796","article-title":"Complement factor B mutations in atypical hemolytic uremic syndrome-disease-relevant or benign?","volume":"25","author":"Marinozzi","year":"2014","journal-title":"J Am Soc Nephrol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"16459","DOI":"10.1074\/jbc.M110.206136","article-title":"Heme interacts with c1q and inhibits the classical complement pathway","volume":"286","author":"Roumenina","year":"2011","journal-title":"J Biol Chem."},{"key":"B32","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.hoc.2015.02.002","article-title":"Thrombotic microangiopathy: focus on atypical hemolytic uremic syndrome","volume":"29","author":"Sperati","year":"2015","journal-title":"Hematol Oncol Clin North Am."},{"key":"B33","doi-asserted-by":"publisher","first-page":"3733","DOI":"10.1182\/blood-2013-12-547067","article-title":"Biomarkers of terminal complement activation confirm the diagnosis of aHUS and differentiate aHUS from TTP","volume":"123","author":"Cataland","year":"2014","journal-title":"Blood"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1161\/HYPERTENSIONAHA.113.01420","article-title":"Urinary excretion of C5b-9 in severe preeclampsia: tipping the balance of complement activation in pregnancy","volume":"62","author":"Burwick","year":"2013","journal-title":"Hypertension"},{"key":"B35","doi-asserted-by":"publisher","first-page":"3253","DOI":"10.1182\/blood-2014-09-600411","article-title":"Eculizumab reduces complement activation, inflammation, endothelial damage, thrombosis, and renal injury markers in aHUS","volume":"125","author":"Cofiell","year":"2015","journal-title":"Blood"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1182\/blood-2014-02-558296","article-title":"Dynamics of complement activation in aHUS and how to monitor eculizumab therapy","volume":"124","author":"Noris","year":"2014","journal-title":"Blood"},{"key":"B37","doi-asserted-by":"publisher","first-page":"2234","DOI":"10.1681\/ASN.2018020184","article-title":"C5b9 Formation on endothelial cells reflects complement defects among patients with renal thrombotic microangiopathy and severe hypertension","volume":"29","author":"Timmermans","year":"2018","journal-title":"J Am Soc Nephrol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"3637","DOI":"10.1182\/blood-2015-02-629683","article-title":"Modified Ham test for atypical hemolytic uremic syndrome","volume":"125","author":"Gavriilaki","year":"2015","journal-title":"Blood"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1182\/blood-2016-07-728253","article-title":"Murine systemic thrombophilia and hemolytic uremic syndrome from a factor H point mutation","volume":"129","author":"Ueda","year":"2017","journal-title":"Blood"},{"key":"B40","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.exphem.2016.01.005","article-title":"Direct evidence of complement activation in HELLP syndrome: a link to atypical hemolytic uremic syndrome","volume":"44","author":"Vaught","year":"2016","journal-title":"Exp Hematol."},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.99128","article-title":"Germline mutations in the alternative pathway of complement predispose to HELLP syndrome","author":"Vaught","year":"2018","journal-title":"JCI Insight"},{"key":"B42","doi-asserted-by":"publisher","first-page":"3748","DOI":"10.1182\/blood-2018-99-119445","article-title":"An alternative pathway specific flow cytometric assay to detect complement activation in atypical hemolytic uremic syndrome (aHUS)","volume":"132","author":"Yu","year":"2018","journal-title":"Blood"},{"key":"B43","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1182\/blood.V126.23.103.103","article-title":"Modified ham test distinguishes aHUS from TTP and predicts response to eculizumab","volume":"126","author":"Gavriilaki","year":"2015","journal-title":"Blood"},{"key":"B44","doi-asserted-by":"publisher","first-page":"466","DOI":"10.3324\/haematol.2016.153312","article-title":"Small-molecule factor D inhibitors selectively block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome","volume":"102","author":"Yuan","year":"2017","journal-title":"Haematologica"},{"key":"B45","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1182\/blood-2015-06-640995","article-title":"Complement in hemolytic anemia","volume":"126","author":"Brodsky","year":"2015","journal-title":"Blood"},{"key":"B46","doi-asserted-by":"publisher","first-page":"2464","DOI":"10.4049\/jimmunol.1701695","article-title":"Statistical validation of rare complement variants provides insights into the molecular basis of atypical hemolytic uremic syndrome and C3 glomerulopathy","volume":"200","author":"Osborne","year":"2018","journal-title":"J Immunol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.2215\/CJN.02210310","article-title":"Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype","volume":"5","author":"Noris","year":"2010","journal-title":"Clin J Am Soc Nephrol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/S0140-6736(17)30062-4","article-title":"Haemolytic uraemic syndrome","volume":"390","author":"Fakhouri","year":"2017","journal-title":"Lancet"},{"key":"B49","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1007\/s00467-010-1555-5","article-title":"Genetics and complement in atypical HUS","volume":"25","author":"Kavanagh","year":"2010","journal-title":"Pediatr Nephrol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"E1445","DOI":"10.1002\/humu.21256","article-title":"Mutations in alternative pathway complement proteins in American patients with atypical hemolytic uremic syndrome","volume":"31","author":"Maga","year":"2010","journal-title":"Hum Mutat."},{"key":"B51","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1055\/s-0034-1375296","article-title":"Genetics of atypical hemolytic uremic syndrome (aHUS)","volume":"40","author":"Rodriguez","year":"2014","journal-title":"Semin Thromb Hemost."},{"key":"B52","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1056\/NEJMoa0810739","article-title":"Thrombomodulin mutations in atypical hemolytic-uremic syndrome","volume":"361","author":"Delvaeye","year":"2009","journal-title":"N Engl J Med."},{"key":"B53","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/ng.2590","article-title":"Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome","volume":"45","author":"Lemaire","year":"2013","journal-title":"Nat Genet."},{"key":"B54","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1182\/blood-2014-06-579953","article-title":"Loss of DGKepsilon induces endothelial cell activation and death independently of complement activation","volume":"125","author":"Bruneau","year":"2015","journal-title":"Blood"},{"key":"B55","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.1007\/s00467-010-1446-9","article-title":"DEAP-HUS: deficiency of CFHR plasma proteins and autoantibody-positive form of hemolytic uremic syndrome","volume":"25","author":"Zipfel","year":"2010","journal-title":"Pediatr Nephrol."},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.e4565","article-title":"Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome: case-control study","author":"Menne","year":"2012","journal-title":"BMJ"},{"key":"B57","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s00467-018-4174-1","article-title":"Hemolytic uremic syndrome associated with Bordetella pertussis infection in a 2-month-old infant carrying a pathogenic variant in complement factor H","volume":"34","author":"Madden","year":"2018","journal-title":"Pediatr Nephrol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1186\/s12882-018-1168-y","article-title":"Treatment of hemolytic uremic syndrome related to Bordetella pertussis infection -is plasma exchange or eculizumab use necessary?","volume":"19","author":"Saida","year":"2018","journal-title":"BMC Nephrol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1093\/cid\/cis196","article-title":"Need for long-term follow-up in enterohemorrhagic Escherichia coli-associated hemolytic uremic syndrome due to late-emerging sequelae","volume":"54","author":"Rosales","year":"2012","journal-title":"Clin Infect Dis."},{"key":"B60","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1093\/cid\/cix218","article-title":"Intermediate follow-up of pediatric patients with hemolytic uremic syndrome during the 2011 outbreak caused by E. coli O104:H4","volume":"64","author":"Loos","year":"2017","journal-title":"Clin Infect Dis."},{"key":"B61","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1086\/644621","article-title":"Hemolytic uremic syndrome and death in persons with Escherichia coli O157:H7 infection, foodborne diseases active surveillance network sites, 2000-2006","volume":"49","author":"Gould","year":"2009","journal-title":"Clin Infect Dis."},{"key":"B62","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1007\/s00467-018-3991-6","article-title":"Hyponatremia: a new predictor of mortality in patients with Shiga toxin-producing Escherichia coli hemolytic uremic syndrome","volume":"33","author":"Alconcher","year":"2018","journal-title":"Pediatr Nephrol"},{"key":"B63","doi-asserted-by":"publisher","first-page":"6394","DOI":"10.4049\/jimmunol.0900151","article-title":"Shiga toxin activates complement and binds factor H: evidence for an active role of complement in hemolytic uremic syndrome","volume":"182","author":"Orth","year":"2009","journal-title":"J Immunol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.2215\/CJN.02730409","article-title":"Alternative pathway of complement in children with diarrhea-associated hemolytic uremic syndrome","volume":"4","author":"Thurman","year":"2009","journal-title":"Clin J Am Soc Nephrol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"5503","DOI":"10.1182\/blood-2010-09-309161","article-title":"Complement activation on platelet-leukocyte complexes and microparticles in enterohemorrhagic Escherichia coli-induced hemolytic uremic syndrome","volume":"117","author":"Stahl","year":"2011","journal-title":"Blood"},{"key":"B66","doi-asserted-by":"publisher","first-page":"11","DOI":"10.21767\/2472-5056.100011","article-title":"Typical hus: evidence of acute phase complement activation from a daycare outbreak","volume":"1","author":"Brady","year":"2016","journal-title":"J Clin Exp Nephrol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"3404","DOI":"10.1681\/ASN.2006050419","article-title":"A murine model of HUS: Shiga toxin with lipopolysaccharide mimics the renal damage and physiologic response of human disease","volume":"17","author":"Keepers","year":"2006","journal-title":"J Am Soc Nephrol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"172","DOI":"10.4049\/jimmunol.1100491","article-title":"Alternative pathway activation of complement by Shiga toxin promotes exuberant C3a formation that triggers microvascular thrombosis","volume":"187","author":"Morigi","year":"2011","journal-title":"J Immunol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"3661","DOI":"10.4049\/jimmunol.1102118","article-title":"Lack of the lectin-like domain of thrombomodulin worsens Shiga toxin-associated hemolytic uremic syndrome in mice","volume":"189","author":"Zoja","year":"2012","journal-title":"J Immunol."},{"key":"B70","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1093\/infdis\/jix633","article-title":"Genetic susceptibility to postdiarrheal hemolytic-uremic syndrome after shiga toxin-producing Escherichia coli infection: a centers for disease control and prevention foodnet study","volume":"217","author":"Kallianpur","year":"2018","journal-title":"J Infect Dis."},{"key":"B71","volume-title":"Executive Summary: Hypertension in Pregnancy","year":"2013"},{"key":"B72","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/S0002-9378(16)32330-4","article-title":"Syndrome of hemolysis, elevated liver enzymes, and low platelet count: a severe consequence of hypertension in pregnancy","volume":"142","author":"Weinstein","year":"1982","journal-title":"Am J Obstet Gynecol."},{"key":"B73","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/0002-9378(86)90266-8","article-title":"Maternal-perinatal outcome associated with the syndrome of hemolysis, elevated liver enzymes, and low platelets in severe preeclampsia-eclampsia","volume":"155","author":"Sibai","year":"1986","journal-title":"Am J Obstet Gynecol."},{"key":"B74","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1016\/S0002-9378(99)70022-0","article-title":"The spectrum of severe preeclampsia: comparative analysis by HELLP (hemolysis, elevated liver enzyme levels, and low platelet count) syndrome classification","volume":"180","author":"Martin","year":"1999","journal-title":"Am J Obstet Gynecol."},{"key":"B75","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1177\/1753495X17704563","article-title":"Pregnancy-induced atypical haemolytic uremic syndrome: a new era with eculizumab","volume":"11","author":"Shanmugalingam","year":"2018","journal-title":"Obstet Med."},{"key":"B76","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/S0002-9378(96)70162-X","article-title":"Clinical utility of strict diagnostic criteria for the HELLP (hemolysis, elevated liver enzymes, and low platelets) syndrome","volume":"175","author":"Audibert","year":"1996","journal-title":"Am J Obstet Gynecol."},{"key":"B77","doi-asserted-by":"publisher","first-page":"467","DOI":"10.2147\/VHRM.S20181","article-title":"Pre-eclampsia: pathophysiology, diagnosis, and management","volume":"7","author":"Uzan","year":"2011","journal-title":"Vasc Health Risk Manag."},{"key":"B78","first-page":"698","article-title":"Enhanced anaphylatoxin and terminal C5b-9 complement complex formation in patients with the syndrome of hemolysis, elevated liver enzymes, and low platelet count","volume":"76","author":"Haeger","year":"1990","journal-title":"Obstet Gynecol."},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001013","article-title":"Mutations in complement regulatory proteins predispose to preeclampsia: a genetic analysis of the PROMISSE cohort","author":"Salmon","year":"2011","journal-title":"PLoS Med."},{"key":"B80","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.bbmt.2005.06.001","article-title":"Blood and marrow transplant clinical trials network toxicity committee consensus summary: thrombotic microangiopathy after hematopoietic stem cell transplantation","volume":"11","author":"Ho","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"key":"B81","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1002\/ajh.20648","article-title":"Risk factor analysis for thrombotic microangiopathy after reduced-intensity or myeloablative allogeneic hematopoietic stem cell transplantation","volume":"81","author":"Nakamae","year":"2006","journal-title":"Am J Hematol."},{"key":"B82","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1097\/01.tp.0000230373.82376.46","article-title":"Risk factors and severe outcome in thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation","volume":"82","author":"Uderzo","year":"2006","journal-title":"Transplantation"},{"key":"B83","doi-asserted-by":"publisher","first-page":"345","DOI":"10.2215\/CJN.02070508","article-title":"Renal thrombotic microangiopathy after hematopoietic cell transplant: role of GVHD in pathogenesis","volume":"4","author":"Changsirikulchai","year":"2009","journal-title":"Clin J Am Soc Nephrol."},{"key":"B84","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1038\/bmt.2009.230","article-title":"Comparison of thrombotic microangiopathy after allogeneic hematopoietic cell transplantation with high-dose or nonmyeloablative conditioning","volume":"45","author":"Willems","year":"2010","journal-title":"Bone Marrow Transplant."},{"key":"B85","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1182\/blood-2014-03-564997","article-title":"Diagnostic and risk criteria for HSCT-associated thrombotic microangiopathy: a study in children and young adults","volume":"124","author":"Jodele","year":"2014","journal-title":"Blood"},{"key":"B86","doi-asserted-by":"publisher","first-page":"95","DOI":"10.3324\/haematol.10699","article-title":"Diagnostic criteria for hematopoietic stem cell transplant-associated microangiopathy: results of a consensus process by an International Working Group","volume":"92","author":"Ruutu","year":"2007","journal-title":"Haematologica"},{"key":"B87","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.1111\/j.1537-2995.2009.02217.x","article-title":"Posttransplant thrombotic microangiopathy: sensitivity of proposed new diagnostic criteria","volume":"49","author":"Kennedy","year":"2009","journal-title":"Transfusion"},{"key":"B88","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1046\/j.1365-2141.2001.02699.x","article-title":"The clinical features, risk factors and outcome of thrombotic thrombocytopenic purpura occurring after bone marrow transplantation","volume":"113","author":"Fuge","year":"2001","journal-title":"Br J Haematol."},{"key":"B89","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1046\/j.1537-2995.2003.00282.x","article-title":"Thrombotic microangiopathy in blood and marrow transplant patients receiving tacrolimus or cyclosporine A","volume":"43","author":"Sarkodee-Adoo","year":"2003","journal-title":"Transfusion"},{"key":"B90","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1055\/s-2006-939765","article-title":"von Willebrand factor-cleaving protease (ADAMTS13) in the course of stem cell transplantation","volume":"32","author":"Kentouche","year":"2006","journal-title":"Semin Thromb Hemost."},{"key":"B91","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1111\/j.1365-2141.2006.06126.x","article-title":"Prospective study on the behaviour of the metalloprotease ADAMTS13 and of von Willebrand factor after bone marrow transplantation","volume":"134","author":"Peyvandi","year":"2006","journal-title":"Br J Haematol."},{"key":"B92","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1182\/blood-2011-02-321315","article-title":"Small vessels, big trouble in the kidneys and beyond: hematopoietic stem cell transplantation-associated thrombotic microangiopathy","volume":"118","author":"Laskin","year":"2011","journal-title":"Blood"},{"key":"B93","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1182\/blood-2013-05-501445","article-title":"Abnormalities in the alternative pathway of complement in children with hematopoietic stem cell transplant-associated thrombotic microangiopathy","volume":"122","author":"Jodele","year":"2013","journal-title":"Blood"},{"key":"B94","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.bbmt.2015.10.002","article-title":"Variable eculizumab clearance requires pharmacodynamic monitoring to optimize therapy for thrombotic microangiopathy after hematopoietic stem cell transplantation","volume":"22","author":"Jodele","year":"2016","journal-title":"Biol Blood Marrow Transplant."},{"key":"B95","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.bbmt.2005.04.007","article-title":"Sirolimus and thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation","volume":"11","author":"Cutler","year":"2005","journal-title":"Biol Blood Marrow Transplant."},{"key":"B96","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1016\/j.bbmt.2008.05.022","article-title":"low body mass index is an independent risk factor for transplant-associated microangiopathy following total-body irradiation-based conditioning regimens","volume":"14","author":"Kaloyannidis","year":"2008","journal-title":"Biol Blood Marrow Transplant."},{"key":"B97","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1111\/j.1440-1827.2011.02704.x","article-title":"Renal thrombotic microangiopathy associated with chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation","volume":"61","author":"Mii","year":"2011","journal-title":"Pathol Int."},{"key":"B98","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.bbmt.2012.10.006","article-title":"Thrombotic microangiopathy associated with sirolimus level after allogeneic hematopoietic cell transplantation with tacrolimus\/sirolimus-based graft-versus-host disease prophylaxis","volume":"19","author":"Shayani","year":"2013","journal-title":"Biol Blood Marrow Transplant."},{"key":"B99","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1002\/hon.2346","article-title":"Transplant-associated thrombotic microangiopathy: an unresolved complication of unrelated allogeneic transplant for hematologic diseases","volume":"35","author":"Sakellari","year":"2017","journal-title":"Hematol Oncol."},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.13371","article-title":"Transplant-associated thrombotic microangiopathy: incidence, prognostic factors, morbidity, and mortality in allogeneic hematopoietic cell transplantation","author":"Gavriilaki","year":"2018","journal-title":"Clin Transplant."},{"key":"B101","doi-asserted-by":"publisher","first-page":"2234","DOI":"10.1172\/JCI61019","article-title":"Antigen-presenting cell-derived complement modulates graft-versus-host disease","volume":"122","author":"Kwan","year":"2012","journal-title":"J Clin Invest."},{"key":"B102","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1016\/j.bbmt.2012.05.014","article-title":"Reduced graft-versus-host disease in C3-deficient mice is associated with decreased donor Th1\/Th17 differentiation","volume":"18","author":"Ma","year":"2012","journal-title":"Biol Blood Marrow Transplant."},{"key":"B103","doi-asserted-by":"publisher","first-page":"2530","DOI":"10.1111\/ajt.12405","article-title":"Immune cell-derived C3a and C5a costimulate human T cell alloimmunity","volume":"13","author":"Cravedi","year":"2013","journal-title":"Am J Transplant."},{"key":"B104","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1038\/bmt.2014.75","article-title":"Complement component C3 mediates Th1\/Th17 polarization in human T-cell activation and cutaneous GVHD","volume":"49","author":"Ma","year":"2014","journal-title":"Bone Marrow Transplant."},{"key":"B105","first-page":"2148","article-title":"Emerging role of C5a\/C5aR IL-17A axis in cGVHD","volume":"10","author":"Chen","year":"2018","journal-title":"Am J Transl Res."},{"key":"B106","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1038\/leu.2011.254","article-title":"Clinical laboratory markers of inflammation as determinants of chronic graft-versus-host disease activity and NIH global severity","volume":"26","author":"Grkovic","year":"2012","journal-title":"Leukemia"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0012162","article-title":"Comparative proteomic analysis of serum from patients with systemic sclerosis and sclerodermatous GVHD","author":"Scambi","year":"2010","journal-title":"PLoS ONE"},{"key":"B108","doi-asserted-by":"publisher","first-page":"2588","DOI":"10.1111\/ajt.13316","volume":"15","author":"Cumpelik","year":"2015","journal-title":"Mechanism of Platelet Activation and Hypercoagulability by Antithymocyte Globulins (ATG). Am J Transplant"},{"key":"B109","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1038\/ni.1923","article-title":"Complement: a key system for immune surveillance and homeostasis","volume":"11","author":"Ricklin","year":"2010","journal-title":"Nat Immunol."},{"key":"B110","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.imlet.2017.05.014","article-title":"The role of CR3 (CD11b\/CD18) and CR4 (CD11c\/CD18) in complement-mediated phagocytosis and podosome formation by human phagocytes","volume":"189","author":"Lukacsi","year":"2017","journal-title":"Immunol Lett."},{"key":"B111","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.molmed.2016.01.004","article-title":"Heme: modulator of plasma systems in hemolytic diseases","volume":"22","author":"Roumenina","year":"2016","journal-title":"Trends Mol Med."},{"key":"B112","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1096\/fj.04-2797fje","article-title":"Airway smooth muscle cells enhance C3a-induced mast cell degranulation following cell-cell contact","volume":"19","author":"Thangam","year":"2005","journal-title":"FASEB J."},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0022559","article-title":"Regulation of C3a receptor signaling in human mast cells by G protein coupled receptor kinases","author":"Guo","year":"2011","journal-title":"PLoS ONE"},{"key":"B114","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1111\/cei.13166","article-title":"Blood clotting and traumatic injury with shock mediates complement-dependent neutrophil priming for extracellular ROS, ROS-dependent organ injury and coagulopathy","volume":"194","author":"Barrett","year":"2018","journal-title":"Clin Exp Immunol."},{"key":"B115","doi-asserted-by":"publisher","first-page":"4794","DOI":"10.4049\/jimmunol.177.7.4794","article-title":"A novel C5a receptor-tissue factor cross-talk in neutrophils links innate immunity to coagulation pathways","volume":"177","author":"Ritis","year":"2006","journal-title":"J Immunol."},{"key":"B116","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.4049\/jimmunol.169.4.2102","article-title":"Complement c3a and c5a induce different signal transduction cascades in endothelial cells","volume":"169","author":"Schraufstatter","year":"2002","journal-title":"J Immunol."},{"key":"B117","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1023\/A:1022362413939","article-title":"Neutrophil adhesion to human endothelial cells is induced by the membrane attack complex: the roles of P-selectin and platelet activating factor","volume":"22","author":"Kilgore","year":"1998","journal-title":"Inflammation"},{"key":"B118","doi-asserted-by":"publisher","first-page":"6921","DOI":"10.4049\/jimmunol.173.11.6921","article-title":"Platelet-activating factor and kinin-dependent vascular leakage as a novel functional activity of the soluble terminal complement complex","volume":"173","author":"Bossi","year":"2004","journal-title":"J Immunol."},{"key":"B119","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1160\/TH15-02-0162","article-title":"Contact activation of C3 enables tethering between activated platelets and polymorphonuclear leukocytes via CD11b\/CD18","volume":"114","author":"Hamad","year":"2015","journal-title":"Thromb Haemost."},{"key":"B120","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.it.2017.03.003","article-title":"Complement C3-targeted therapy: replacing long-held assertions with evidence-based discovery","volume":"38","author":"Mastellos","year":"2017","journal-title":"Trends Immunol."},{"key":"B121","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1055\/s-0030-1262890","article-title":"Plasmatherapy in atypical hemolytic uremic syndrome","volume":"36","author":"Loirat","year":"2010","journal-title":"Semin Thromb Hemost."},{"key":"B122","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1182\/blood-2005-10-007252","article-title":"Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome","volume":"108","author":"Caprioli","year":"2006","journal-title":"Blood"},{"key":"B123","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/nrneph.2017.156","article-title":"The renaissance of complement therapeutics","volume":"14","author":"Ricklin","year":"2018","journal-title":"Nat Rev Nephrol."},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2013-003573","article-title":"A systematic review of eculizumab for atypical haemolytic uraemic syndrome (aHUS)","author":"Rathbone","year":"2013","journal-title":"BMJ Open"},{"key":"B125","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1038\/ki.2014.423","article-title":"Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies","volume":"87","author":"Licht","year":"2015","journal-title":"Kidney Int."},{"key":"B126","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.kint.2015.11.026","article-title":"Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome","volume":"89","author":"Greenbaum","year":"2016","journal-title":"Kidney Int."},{"key":"B127","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1053\/j.ajkd.2015.12.034","article-title":"Terminal complement inhibitor eculizumab in adult patients with atypical hemolytic uremic syndrome: a single-arm, open-label trial","volume":"68","author":"Fakhouri","year":"2016","journal-title":"Am J Kidney Dis."},{"key":"B128","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1007\/s10157-018-1610-2","article-title":"Safety and effectiveness of eculizumab for pediatric patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance","volume":"23","author":"Ito","year":"2018","journal-title":"Clin Exp Nephrol"},{"key":"B129","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s10157-018-1609-8","article-title":"Safety and effectiveness of eculizumab for adult patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance","volume":"23","author":"Kato","year":"2018","journal-title":"Clin Exp Nephrol"},{"key":"B130","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1038\/nrneph.2012.214","article-title":"Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies","volume":"8","author":"Zuber","year":"2012","journal-title":"Nat Rev Nephrol."},{"key":"B131","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.ejim.2013.05.007","article-title":"Atypical hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: clinically differentiating the thrombotic microangiopathies","volume":"24","author":"Cataland","year":"2013","journal-title":"Eur J Intern Med."},{"key":"B132","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1056\/NEJMc1308826","article-title":"Eculizumab in atypical hemolytic-uremic syndrome","volume":"369","author":"Legendre","year":"2013","journal-title":"N Engl J Med."},{"key":"B133","doi-asserted-by":"publisher","first-page":"2804","DOI":"10.1182\/blood-2014-02-522128","article-title":"Paroxysmal nocturnal hemoglobinuria","volume":"124","author":"Brodsky","year":"2014","journal-title":"Blood"},{"key":"B134","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1016\/j.bbmt.2016.03.032","article-title":"Terminal complement blockade after hematopoietic stem cell transplantation is safe without meningococcal vaccination","volume":"22","author":"Jodele","year":"2016","journal-title":"Biol Blood Marrow Transplant."},{"key":"B135","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1053\/j.ajkd.2014.01.434","article-title":"Discontinuation of eculizumab maintenance treatment for atypical hemolytic uremic syndrome: a report of 10 cases","volume":"64","author":"Ardissino","year":"2014","journal-title":"Am J Kidney Dis."},{"key":"B136","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/qjmed\/hcv082","article-title":"A national specialized service in England for atypical haemolytic uraemic syndrome-the first year's experience","volume":"109","author":"Sheerin","year":"2016","journal-title":"QJM"},{"key":"B137","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1093\/ckj\/sfw115","article-title":"Current evidence on the discontinuation of eculizumab in patients with atypical haemolytic uraemic syndrome","volume":"10","author":"Macia","year":"2017","journal-title":"Clin Kidney J."},{"key":"B138","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1182\/blood-2017-02-770214","article-title":"Eculizumab cessation in atypical hemolytic uremic syndrome","volume":"130","author":"Merrill","year":"2017","journal-title":"Blood"},{"key":"B139","doi-asserted-by":"publisher","first-page":"50","DOI":"10.2215\/CJN.06440616","article-title":"Pathogenic variants in complement genes and risk of atypical hemolytic uremic syndrome relapse after eculizumab discontinuation","volume":"12","author":"Fakhouri","year":"2017","journal-title":"Clin J Am Soc Nephrol."},{"key":"B140","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1007\/s00277-012-1622-z","article-title":"Relapse of aHUS after discontinuation of therapy with eculizumab in a patient with aHUS and factor H mutation","volume":"92","author":"Carr","year":"2013","journal-title":"Ann Hematol."},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1097\/MPH.0000000000000505","article-title":"Disease recurrence after early discontinuation of eculizumab in a patient with atypical hemolytic uremic syndrome with complement C3 I1157T mutation","author":"Toyoda","year":"2016","journal-title":"J Pediatr Hematol Oncol"},{"key":"B142","doi-asserted-by":"publisher","first-page":"e93","DOI":"10.1111\/j.1432-2277.2012.01497.x","article-title":"Eculizumab for the treatment of two recurrences of atypical hemolytic uremic syndrome in a kidney allograft","volume":"25","author":"Alachkar","year":"2012","journal-title":"Transpl Int."},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-018-4091-3.","article-title":"Eculizumab in atypical hemolytic uremic syndrome: strategies toward restrictive use","author":"Wijnsma","year":"2018","journal-title":"Pediatr Nephrol."},{"key":"B144","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1038\/nrd4657","article-title":"Complement, a target for therapy in inflammatory and degenerative diseases","volume":"14","author":"Morgan","year":"2015","journal-title":"Nat Rev Drug Discov."},{"key":"B145","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1053\/j.seminhematol.2018.02.002","article-title":"Expanding complement therapeutics for the treatment of paroxysmal nocturnal hemoglobinuria","volume":"55","author":"Mastellos","year":"2018","journal-title":"Semin Hematol."},{"key":"B146","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1182\/blood.V128.22.2431.2431","article-title":"Evaluation of bacteria-mediated potential \u201cbystander\u201d hemolysis of PNH RED CELLS in vitro: no evidence of significant complement classical or lectin pathway-mediated hemolysis induced by microorganisms","volume":"128","author":"Yuan","year":"2016","journal-title":"Blood"},{"key":"B147","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1182\/blood-2017-05-781450","article-title":"Eculizumab treatment and impaired opsonophagocytic killing of meningococci by whole blood from immunized adults","volume":"130","author":"Konar","year":"2017","journal-title":"Blood"},{"key":"B148","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1111\/eci.12419","article-title":"Compstatin: a C3-targeted complement inhibitor reaching its prime for bedside intervention","volume":"45","author":"Mastellos","year":"2015","journal-title":"Eur J Clin Invest."},{"key":"B149","doi-asserted-by":"publisher","first-page":"6020","DOI":"10.4049\/jimmunol.1400569","article-title":"Genetic and intervention studies implicating complement C3 as a major target for the treatment of periodontitis","volume":"192","author":"Maekawa","year":"2014","journal-title":"J Immunol."},{"key":"B150","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1111\/j.1365-3083.2006.01729.x","article-title":"Clinical aspects and molecular basis of primary deficiencies of complement component C3 and its regulatory proteins factor I and factor H","volume":"63","author":"Reis","year":"2006","journal-title":"Scand J Immunol."},{"key":"B151","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.clim.2018.09.004","article-title":"Safety profile after prolonged C3 inhibition","volume":"197","author":"Reis","year":"2018","journal-title":"Clin Immunol."},{"key":"B152","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1056\/NEJMc1100859","article-title":"Eculizumab in severe Shiga-toxin-associated HUS","volume":"364","author":"Lapeyraque","year":"2011","journal-title":"N Engl J Med."},{"key":"B153","doi-asserted-by":"publisher","first-page":"117","DOI":"10.2146\/ajhp140134","article-title":"Safe and effective use of eculizumab in the treatment of severe Shiga toxin Escherichia coli-associated hemolytic uremic syndrome","volume":"72","author":"Dinh","year":"2015","journal-title":"Am J Health Syst Pharm."},{"key":"B154","doi-asserted-by":"publisher","first-page":"3807","DOI":"10.1093\/ndt\/gfs394","article-title":"Best supportive care and therapeutic plasma exchange with or without eculizumab in Shiga-toxin-producing E. coli O104:H4 induced haemolytic-uraemic syndrome: an analysis of the German STEC-HUS registry","volume":"2","author":"Kielstein","year":"2012","journal-title":"Nephrol Dial Transplant."},{"key":"B155","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1007\/s00467-018-3903-9","article-title":"Eculizumab treatment in severe pediatric STEC-HUS: a multicenter retrospective study","volume":"33","author":"Percheron","year":"2018","journal-title":"Pediatr Nephrol."},{"key":"B156","doi-asserted-by":"publisher","first-page":"11037","DOI":"10.1038\/ncomms11037","article-title":"Coagulation induced by C3aR-dependent NETosis drives protumorigenic neutrophils during small intestinal tumorigenesis","volume":"7","author":"Guglietta","year":"2016","journal-title":"Nat Commun."},{"key":"B157","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/j.ajog.2005.08.044","article-title":"Understanding and managing HELLP syndrome: the integral role of aggressive glucocorticoids for mother and child","volume":"195","author":"Martin","year":"2006","journal-title":"Am J Obstet Gynecol."},{"key":"B158","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1097\/AOG.0000000000000140","article-title":"Risk factors, management, and outcomes of hemolysis, elevated liver enzymes, and low platelets syndrome and elevated liver enzymes, low platelets syndrome","volume":"123","author":"Fitzpatrick","year":"2014","journal-title":"Obstet Gynecol."},{"key":"B159","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.placenta.2012.11.014","article-title":"Eculizumab for the treatment of preeclampsia\/HELLP syndrome","volume":"34","author":"Burwick","year":"2013","journal-title":"Placenta"},{"key":"B160","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1056\/NEJMoa1502950","article-title":"Eculizumab in pregnant patients with paroxysmal nocturnal hemoglobinuria","volume":"373","author":"Kelly","year":"2015","journal-title":"N Engl J Med."},{"key":"B161","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1111\/j.1537-2995.2004.00700.x","article-title":"Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome following allogeneic HPC transplantation: a diagnostic dilemma","volume":"44","author":"George","year":"2004","journal-title":"Transfusion"},{"key":"B162","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1097\/TP.0000000000000601","article-title":"Use of eculizumab in patients with allogeneic stem cell transplant-associated thrombotic microangiopathy: a study from the SFGM-TC","volume":"99","author":"de","year":"2015","journal-title":"Transplantation"},{"key":"B163","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1038\/bmt.2016.87","article-title":"Eculizumab therapy in adults with allogeneic hematopoietic cell transplant-associated thrombotic microangiopathy","volume":"51","author":"Vasu","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"B164","doi-asserted-by":"publisher","first-page":"2172","DOI":"10.1016\/j.bbmt.2017.08.019","article-title":"Thrombotic microangiopathy after allogeneic stem cell transplantation: a comparison of eculizumab therapy and conventional therapy","volume":"23","author":"Bohl","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"B165","doi-asserted-by":"publisher","first-page":"2090","DOI":"10.1182\/bloodadvances.2018019596","article-title":"Complement-mediated thrombotic microangiopathy associated with lupus nephritis","volume":"2","author":"Park","year":"2018","journal-title":"Blood Adv."}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2019.00337\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T02:05:15Z","timestamp":1574129115000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2019.00337\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,27]]},"references-count":165,"alternative-id":["10.3389\/fimmu.2019.00337"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2019.00337","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,27]]},"article-number":"337"}}